|Videos|September 30, 2020

COVID-19 Public Health Messaging Needs to Improve

Brad Spellberg, MD, describes the inconsistent, impersonal messaging given to the public as cases begin to rise again.

The occurrence of the US reaching 200,000 deaths from the coronavirus 2019 (COVID-19) pandemic last week aligned with a rise in daily new cases to 50,000-plus—a return to midsummer highs being reported when cases spiked throughout southern and western regions.

It warrants clarification: is this the second wave of COVID-19 in the US? Or were those summertime spikes the second wave?

To Brad Spellberg, MD, the question is a moot point: there is little singularity in how the pandemic is affecting the country.

“It is difficult to talk about the number of peaks and waves, because in the United States, we don’t have 1 pandemic,” he said. “We have a thousand different pandemics, because the jurisdiction or responsibility for combating the virus has been left to local public health offices, states, and municipalities.”

In an interview with Contagion®, Spellberg, the chief medical officer of the Los Angeles County and University of Southern California Medical Center, discussed the “whack-a-mole” phenomenon of COVID-19 spread as it rises again in the early fall season: one region seemingly having managed the virus for weeks on end suddenly becomes a hotspot.

Spellberg emphasized the need for a unified response to the pandemic—a tall order given what he called a “hyperpolarization” of rhetoric.

“Our problems are not scientific,” Spellberg said. “Our problems are political. Our problems are civil discourse.”

What message gets through in the end is one that values the wellbeing and interests of the individual. Messaging on the pandemic should follow suit.

“We have to respect and understand human nature if we’re going to get people to do what we want them to do,” Spellberg said.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.